IL6R and neoplasm: Mice treated with combination virotherapy and IL-1β or IL-6R blockade had slightly, but not significantly reduced tumor volumes and enhanced survival (Fig. 2C–F), which could potentially be attributed to the greater concentrations of IL-1β and IL-6 within the tumor being more difficult to fully block with therapeutic antibodies (Fig. 1E).